Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.